Neuroblastoma

Additionally, following lipidation, all protective apoE variants were found to enhance the viability of SK-N-SH neuroblastoma cells and reduce the production of TNFα from BV2 microglia cells. Overall, these findings suggest that the specific amino acid changes found in AD-protective apoE variants can induce changes in the molecule's stability and conformation that may underlie common functional consequences, which are independent of the apoE background.

MALAT1 rs619586 A > G and rs3200401 C > T significantly contribute to susceptibility to neuroblastoma, and further research is needed to investigate the underlying mechanisms involved.

Allo-HCT can be a platform for treating NBL using combination ex vivo stimulated allogeneic NK cell therapy with TIM-3 blockade to enhance the GVT effect without inducing GVHD.

German Clinical Trial Registry: DRKS00023442 Keywords: Pediatrics, MR-Imaging, Nervous-Peripheral, Fractal Analysis, Tissue Characterization, Tumor Response Supplemental material is available for this article.

This study demonstrates that INS, IGF-1, and IGF-2 regulate Rho GTPase and MRTFA activation, thereby contributing to the control of actin cytoskeletal dynamics in neuronal cells. Given the role of INS and IGFs in neuronal survival and neurodegenerative conditions, elucidating these mechanisms is of critical importance, as it offers insights into disease pathogenesis and potential therapeutic targets.

Conversely, neuroblastoma models with in-frame deletions mount an appropriate epigenetic response to RA. Taken together this shows that the mechanism of differentiation in ATRX-altered neuroblastoma depends on the type of ATRX alteration, with implications relating to both oncogenesis and therapeutic response.

In the third edition of this Special Issue, the participating researchers focused their studies on bispecific antibodies against solid tumors [contribution 1], teratoma development [contribution 2], the seminoma microenvironment [contribution 3], neuroblastoma and peptidergic systems [contribution 4], hepatocellular carcinoma [contribution 5], the synthesis of novel podophyllotoxin-benzothiazole congeners for use as anticancer agents [contribution 6], the effects of podophyllotoxin derivatives on non-cancerous diseases [contribution 7], and the involvement of the aryl hydrocarbon receptor and the signal transducer and activator of transcription 3 in chemical carcinogenesis [contribution 8] [...].

The study provides a TT-focused prospective analysis still rare in pediatric oncology. The outcomes indicate satisfactory tolerance and promising efficacy of TT, prompting an update of current treatment standards for several pediatric cancers.

Based on these results, sweet orange EO and its main component, (+)-limonene, can be considered as neuroprotective agents and are promising candidates for complementary therapy in Parkinson's disease.

Collectively, our findings indicate that while PrPC facilitates early events in αS aggregate interaction with neurons, the sustained neurotoxicity induced by αS prefibrillar oligomers and fibrils is predominantly mediated by extracellular Ca2+. This promotes aggregate-membrane interactions, membrane permeabilization, and intracellular Ca2+ dyshomeostasis, thereby establishing a vicious cycle of neuronal dysfunction and death.

CRISPR-mediated CXCL10 knock-in enhances CAR T cell infiltration and antitumour efficacy in vitro and in vivo, including humanized CD34⁺ HuNOG mice, where CXCL10-expressing tumours show stronger immune infiltration and prolonged tumour control within a reconstituted human immune microenvironment. Our findings establish a framework for safe and effective CRISPR-based cytokine delivery, integrating localized TME remodelling with cellular immunotherapies to enhance CAR T cells and other treatments in immune-refractory solid tumours.

This study identified and validated four EM-related prognostic biomarkers in neuroblastoma, with GNG12 functionally implicated in tumor cell proliferation and migration. These findings provide potential therapeutic targets and prognostic indicators for neuroblastoma management.